ire, a validated screening
measure for RBD, researchers determined that 8 percent of these individuals
had probable RBD. Twenty-one percent with probable RBD had anxiety and 11.5
percent had apathy (compared with 8 percent and 4 percent, respectively,
for individuals without RBD). Those individuals with RBD had significantly
lower scores on neuropsychological measures of attention and executive
functioning, such as concentration, decision making, and higher-order
problem solving. Additionally, researchers found that 1.8 percent of the
individuals had both RBD and parkinsonism.
"There is currently no treatment to delay the onset or prevent dementia
or parkinsonism in patients with RBD who are destined to develop these
neurologic problems in the future," says Dr. Boeve. "Our ultimate goal is
to use therapies that would delay the onset or prevent these problems from
ever developing in patients who have a form of RBD that reflects an
evolving neurodegenerative disease. However, much more research is needed
to get to that point."
Dr. Boeve and his team will continue to study this group of patients to
better understand how RBD is associated with neurodegenerative disease.
Other members of the Mayo Clinic research team included Jennifer Molano,
M.D., Ebru Mihci, M.D., Rosebud Roberts, M.B.Ch.B., Yonas Geda, M.D., David
Knopman, M.D., Eric Tangalos, M.D., Glenn Smith, Ph.D., Robert Ivnik,
Ph.D., Ruth Cha, V. Shane Pankratz, Ph.D., Michael Silber, M.B.Ch.B., Tanis
Ferman, Ph.D., and Ronald Petersen, M.D., Ph.D.
To obtain the latest news releases from Mayo Clinic, go to
http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is available
as a resource for your health stories.
'/>"/>SOURCE Mayo Clinic Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine technology :1.
Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia2.
Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab3.
MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-134.
Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing5.
Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease6.
Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data7.
Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference8.
Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model9.
Presentation of HeartWare Clinical Results10.
Clinically Proven Treatment Offers Help to Rosacea Sufferers11.
Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling